Terns Pharmaceuticals (TERN) Stock Analysis: AI Score & Alternative Data
Alt-data signals are cooling for Terns Pharmaceuticals
Is Terns Pharmaceuticals a buy right now? The alternative data says hold. This TERN stock analysis is built on the 25+ alternative data signals AltIndex tracks on Terns Pharmaceuticals every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 52/100: a Hold. The stock trades at $52.95 with a $6B market cap.
The soft spots over the past 90 days: web traffic down 56.2% to 2K monthly visits, and headcount (according to LinkedIn) down 14.5% to 59 employees. The rest of the signal set is holding steady, which keeps TERN at a hold rather than a sell.
TERN’s broader alt-data profile also covers X followers (346), Reddit mentions (1 a day), and sentiment (33/100). Every signal links to its own page with full history, the TERN technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on TERN is just below.
Terns Pharmaceuticals AI Stock Analysis
Terns Pharmaceuticals is a biopharmaceutical company focused on discovering and developing innovative therapies to address serious diseases with significant unmet medical need. The company specializes in treatments for liver disease and oncology, prioritizing high-potential targeted therapies that have the potential to dramatically improve patient outcomes.
Analysis generated October 2, 2026.
Recent Terns Pharmaceuticals Stock Alerts
|
Terns Pharmaceuticals | April 3 Insider Alert: Kuriakose Emil is selling shares |
|
Terns Pharmaceuticals | March 18 Insider Alert: Burroughs Amy L. is selling shares |
|
Terns Pharmaceuticals | March 13 Price is up by 6.2% in the last 24h. |
|
Terns Pharmaceuticals | March 12 Price is down by -6.2% in the last 24h. |
Terns Pharmaceuticals Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 2K | 56.2% | |
| Job Posts | 0 | 100.0% | |
| LinkedIn Employees | 59 | 14.5% | |
| Sentiment | 33 | 0% | |
| Reddit Mentions | 1 | N/A | |
| X Mentions | 41 | 4,000.0% | |
| Stocktwits Mentions | 3 | 0% | |
| News Mentions | 0 | N/A | |
| Stocktwits Subscribers | 2K | 3.9% | |
| 4chan Mentions | 0 | N/A | |
| X Followers | 346 | 0% |
About Terns Pharmaceuticals (TERN)
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity.
| Price | $52.95 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $6B |
| Year Range | $8 – $53 |
| Dividend Yield | 0% |
| PE Ratio | — |
| Analyst Rating | 38% buy |
| Industry | Biotechnology |
Latest Terns Pharmaceuticals News
View more →
Terns Pharmaceuticals Announces FDA Breakthrough Therapy Designation Granted to TERN-701 for Certain Patients with Chronic Myeloid LeukemiaApril 27 - GlobeNewswire |
|
Shareholder Alert: Ademi LLP investigates whether Terns Pharmaceuticals Inc. is obtaining a Fair Price for Public ShareholdersApril 7 - GlobeNewswire |
|
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)April 2 - GlobeNewswire |
|
Merck to acquire Terns Pharmaceuticals for $6.7BMarch 25 - Yahoo Entertainment |
|
 |
Merck to buy Terns Pharmaceuticals for $6.7 billion to boost cancer pipelineMarch 25 - CNBC |
See Terns Pharmaceuticals’s complete price and AI Score history
Sign up to unlock 1-year and all-time charts for TERN, plus 25+ alternative data signals, AI Scores, and real-time alerts.
Get Started for FREETerns Pharmaceuticals Earnings & Financial Performance
View all earnings →Terns Pharmaceuticals Insider Trading Activity
View all →| Kuriakose Emil filed to sell 105,673 shares at $0.0. Apr 1 '26 |
| Burroughs Amy L. filed to sell 288,976 shares at $0.0. Mar 16 '26 |
| Burroughs Amy L. filed to sell 291,746 shares at $0.0. Mar 16 '26 |
| Burroughs Amy L. filed to sell 301,218 shares at $0.0. Feb 17 '26 |
| Burroughs Amy L. filed to sell 288,976 shares at $0.0. Feb 17 '26 |
Terns Pharmaceuticals Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| No congress trades on file. | |||
Stocks Similar to Terns Pharmaceuticals
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
GrailGRAL |
$131.50 4.2% | $6B | 52 |
 |
Centessa PharmaceuticalsCNTA |
$40.50 0.8% | $6B | 49 |
 |
Ligand PharmaceuticalsLGND |
$296.44 0.2% | $6B | 53 |
 |
Kodiak SciencesKOD |
$91.21 1.2% | $6B | 58 |
 |
Iovance BiotherapeuticsIOVA |
$12.56 3.1% | $6B | 53 |
Explore Terns Pharmaceuticals Data
Frequently Asked Questions: Terns Pharmaceuticals (TERN)
Terns Pharmaceuticals has an AltIndex AI Score of 52/100 (Hold). The score reflects mixed alternative data signals. All investments carry risk.
52/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of Terns Pharmaceuticals (TERN) stock is $52.95 with a market cap of $6B.
As of today, Terns Pharmaceuticals’s PE (Price to Earnings) ratio is —.
View the latest Terns Pharmaceuticals insider transactions to see recent buying and selling activity by company executives and directors.
Check the Terns Pharmaceuticals congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The TERN stock price chart above shows Terns Pharmaceuticals’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full Terns Pharmaceuticals technical analysis for RSI, moving averages, and more.
See the stocks similar to Terns Pharmaceuticals section on this page for companies in the same industry ranked by market cap and AI Score.
